XML 33 R21.htm IDEA: XBRL DOCUMENT

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company has signed a new lease at 233 Wilshire Blvd., Suite 400 Santa Monica, CA. The lease is for 5 years and this is the new corporate address. On January 4, 2022, the Company issued restricted stock units ("RSUs") to employees for 135,475 shares of Common Stock. The price of the Common Stock on the date of issuance was $32.85 per share. The RSUs were issued under the 2017 Plan. The RSUs vest 1/3 each year for the next three years on the anniversary of the grant date. On January 4, 2022, the Company issued performance stock units ("PSUs") to certain employees for 80,735 shares of Common Stock. The price of the Common Stock on the date of issuance was $32.85 per share. The PSUs were issued under the 2017 Plan. The PSUs vest equally at 25% upon the achievement of various performance milestones. On January 24, 2022, the Company announced a modification to its contract with BARDA for an additional commitment of up to $2.2 million to support OPNT003, nasal nalmefene, for opioid overdose. The increase in funding is primarily directed toward the costs of the Company's clinical studies to support its submission of OPNT003 to the FDA. During Q1 2022, Pontifax Medisen Finance ("Pontifax") voluntarily converted approximately $1.4 million of the outstanding $7.9 million convertible debt held by Pontifax into a total of 70,000 shares of common stock at a conversion rate of $19.64 per share. In addition, Kreos Capital ("Kreos") voluntarily converted approximately $1 million of the outstanding $9 million convertible debt held by Kreos into a total of 50,916 shares of common stock at a conversion rate of $19.64 per share. During Q1 of 2022, the Company issued 31,746 shares of Common Stock for RSU's that vested during January, and the Company issued 7,097 shares of Common Stock from stock option exercises.